Renal function effect of ARV combination regimen Tenofovir/Lamivudine/Dolutegravir and Tenofovir/Emtricitabine/Rilpivirine in HIV patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20241030006

Enrollment

200

Registered

2024-10-30

Start date

2023-06-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV patients who on treatment with TDF/3TC/DTG and TDF/FTC + RPV Estimated glomerular filtration rate, Dolutegravir, Rilpivirine

Interventions

HIV patients who switch treatment to TDF/3TC/DTG by infectious doctor,HIV patients who switch treatment to TDF/FTC + RPV by infectious doctor

Treatment,Treatment

TDF/3TC/DTG,TDF/FTC + RPV

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: HIV-infected patients who had previously received ART and achieved viral suppression

Exclusion criteria

Exclusion criteria: 1. No information is recorded in the medical records, or the data to be studied is incomplete. 2. other medications are being taken that affect kidney function. 3. Individuals who have switched antiretroviral regimens outside the study period.

Design outcomes

Primary

Measure	Time frame
mean changes in estimated glomerular filtration rate 12, 24, and 48 weeks. Generalized Estimating Equations.	—

Secondary

Measure	Time frame
N/A N/A N/A	—

Countries

Thailand

Contacts

Public ContactSuchart Jenkriangkrai

Maharat Nakhon Ratchasima hospital

suchartjen@hotmail.com0818782408

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026